Frontlight ResearchEarly access
Liver and biliary tract cancer trials in Italy
88 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 17 November 2026. Ask the study team whether a trial fits you.
- Phase 2Not yet taking people in ItalyPrevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
- Where
- Padova, Rome
- Age
- 18 years and over
- People
- 70
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to join2026-526857-33-00 - Phase 1/2Taking peopleA Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- Where
- Naples, Padova, Roma, Rozzano
- Age
- 18 years and over
- People
- 630 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06427941 · EU 2025-524136-19-00 - Phase 2/3Taking peopleCisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
- Where
- Ancona, Bergamo, Bologna, Brescia, Cuneo, Meldola, Milan, Modena, Monza, Padova, Pavia, Pisa, Ravenna, Rome, Turin, Verona
- Age
- 18 years to 75 years
- People
- 300
- Run by
- Gruppo Oncologico del Nord-Ovest
See details and how to joinNCT06037980 - No phaseTaking peopleNew Diagnostic Criteria in the Evaluation Response to Ablation Treatment of Hepatocellular Carcinoma Nodules
- Where
- Roma
- Age
- 18 years and over
- People
- 200
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT07272083 - Phase 2Active, not recruitingStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
- Where
- Bologna, Rozzano, Verona
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Taiho Oncology, Inc.
See details and how to joinNCT05727176 · EU 2023-503665-39-00 - Phase 3Taking peopleA Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician’s Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR) altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma (FIRST-308)
- Where
- Ancona, Candiolo, Meldola, Milan, Naples, Pisa, Rozzano, Siena, Verona
- Age
- 18 years and over
- People
- 126 worldwide
- Run by
- Transthera Sciences (Nanjing) Inc.
See details and how to join2023-505660-11-00 - Phase 2/3Not yet taking people in ItalyThe HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
- Where
- Avellino, Aviano, Bergamo, Caserta, Cuneo, Frattamaggiore, Messina, Naples, Novara, Orbassano, Peschiera del Garda, Rome, Rozzano, Tricase
- Age
- 18 years and over
- People
- 1,700
- Run by
- Azienda Sanitaria Locale Napoli 1 Centro
See details and how to join2026-525898-39-00 - Phase 2Not yet taking people in ItalyA PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2
- Where
- Ancona, Milan, Monserrato, Naples, Pisa, Rome, Turin
- Age
- 18 years and over
- People
- 56
- Run by
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
See details and how to join2025-521608-23-00 - No phaseEnrolling by invitationSafety and Economics of Parenchymal Transection in Minimally Invasive Liver Surgery
- Where
- Campobasso
- Age
- 18 years and over
- People
- 800
- Run by
- University of Molise
See details and how to joinNCT07750275 - Phase 2Taking peopleA Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- Where
- Meldola, Milan, Naples
- Age
- 8 years and over
- People
- 254 worldwide
- Run by
- Fore Biotherapeutics
See details and how to joinNCT05503797 · EU 2024-513578-23-00 - Phase 1Taking peopleA Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
- Where
- Bologna, Milan, Verona
- Age
- 18 years and over
- People
- 714 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT05208762 · EU 2023-506604-18-00 - Phase 2Taking peopleRandomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus Bevacizumab Alone in Metastatic Colorectal Cancer Patients
- Where
- Milan
- Age
- 18 years and over
- People
- 35 worldwide
- Run by
- Delcath Systems Inc.
See details and how to join2024-520356-24-00 - No phaseNot yet taking people in ItalyPatients With Hepatocellular Carcinoma (HCC)
- Where
- Roma
- Age
- 18 years and over
- People
- 52
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT07690683 - Phase 2Taking peopleStudy on the effect of 2 immunotherapy drugs in combination with radioactive glass spheres on the survival in liver cancer
- Where
- Pisa
- Age
- 18 years and over
- People
- 64 worldwide
- Run by
- Klinikum der Universitaet Muenchen AöR
See details and how to join2024-515127-11-00 - No phaseTaking peopleSan Raffaele Registry on Liver Cancer
- Where
- Milan
- Age
- 18 years and over
- People
- 4,000
- Run by
- IRCCS San Raffaele
See details and how to joinNCT07704489 - Phase 1/2Taking peopleA Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
- Where
- Milan, Ravenna, Rossano, Siena
- Age
- 18 years and over
- People
- 180 worldwide
- Run by
- Alentis Therapeutics AG
See details and how to joinNCT07169734 · EU 2025-521441-24-00 - No phaseTaking peopleEvaluation of Tissue and Circulating microRNA Profiles in Patients With Hepatocellular Carcinoma Subjected to Thermal Ablation
- Where
- Bologna
- Age
- 18 years to 64 years
- People
- 150
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT07601464 - No phaseNot yet taking people in ItalyOutcomes After Liver and Biliary Resection at a High-Volume Center
- Where
- Pistoia
- Age
- 18 years and over
- People
- 1,000
- Run by
- Azienda USL Toscana Centro
See details and how to joinNCT07556835 - No phaseTaking peopleElectrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype
- Where
- Padova
- Age
- 18 years to 99 years
- People
- 24
- Run by
- Istituto Oncologico Veneto IRCCS
See details and how to joinNCT06753136 - No phaseTaking peopleLIver TrAnspLantation for Non-resectable Peri-HIlar cholangioCArcinoma (LITALHICA)
- Where
- Padova
- Age
- 18 years to 70 years
- People
- 50
- Run by
- Azienda Sanitaria Ospedaliera
See details and how to joinNCT06125769 - No phaseTaking peopleThe MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- Where
- Brescia, Negrar
- Age
- 18 years and over
- People
- 8,000 worldwide
- Run by
- UMC Utrecht
See details and how to joinNCT04075305 - No phaseTaking peopleItalian Group of Regenerative and Occlusive Worldwide-used Techniques of Hepatic Hypertrophy
- Where
- Bologna
- Age
- 18 years and over
- People
- 2,000
- Run by
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
See details and how to joinNCT07445412 - No phaseTaking peopleDecoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches
- Where
- Milan
- Age
- 18 years and over
- People
- 270
- Run by
- Niguarda Hospital
See details and how to joinNCT07432347 - No phaseTaking peopleChanges in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
- Where
- Roma
- Age
- 18 years and over
- People
- 20
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
See details and how to joinNCT07429864 - Phase 4Taking peopleEffect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
- Where
- Milan, Roma, Siena, Trieste, Verona
- Age
- 18 years to 64 years
- People
- 2,076 worldwide
- Run by
- Guerbet
See details and how to joinNCT04373564